Occurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma

被引：1
|
作者：
Zimmermann, Julian [1 ]
Esser, E. [1 ]
Eter, N. [1 ]
Schuett, P. [2 ]
Uhlig, C. E. [1 ]
机构：
[1] Univ Klinikum Munster, Klin Augenheilkunde, Domagkstr 15, D-48149 Munster, Germany
[2] Onkol Gemeinschaftspraxis, Gutersloh, Germany
来源：
OPHTHALMOLOGIE | 2023年 / 120卷 / 07期
关键词：
D O I：
10.1007/s00347-022-01700-9
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：747 / 750
页数：4
相关论文
共 50 条
  • [31] FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma
    Baines, Andrea C.
    Ershler, Rachel
    Kanapuru, Bindu
    Xu, Qing
    Shen, Guoxiang
    Li, Liang
    Ma, Lian
    Okusanya, Olanrewaju O.
    Simpson, Natalie E.
    Nguyen, Wanda
    Theoret, Marc R.
    Pazdur, Richard
    Gormley, Nicole J.
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4629 - 4633
  • [32] The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
    Diaz, Adrian Alfonso Almodovar
    Alouch, Samhar Samer
    Chawla, Yogesh
    Gonsalves, Wilson, I
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2024, 14 : 71 - 87
  • [33] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Suzanne Trudel
    Arleigh McCurdy
    Martha L. Louzada
    Stephen Parkin
    Darrell White
    Michael P. Chu
    Rami Kotb
    Hira Mian
    Ibraheem Othman
    Jiandong Su
    Aniba Khan
    Engin Gul
    Donna Reece
    Nature Medicine, 2024, 30 : 543 - 551
  • [34] The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development
    Mukhopadhyay, Pralay
    Abdullah, Hesham A.
    Opalinska, Joanna B.
    Paka, Prani
    Richards, Eric
    Weisel, Katja
    Trudel, Suzanne
    Mateos, Maria-Victoria
    Dimopoulos, Meletios Athanasios
    Lonial, Sagar
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [35] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [36] OUTCOMES OF IDECABTAGENE VICLEUCEL IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH BELANTAMAB MAFODOTIN
    Melody, Megan
    Przybylski, Daniel
    Robinson, Adam
    Lin, Adam
    Gordon, Leo
    Adekola, Kehinde
    Singhal, Seema
    Mehta, Jayesh
    Moreira, Jonathan
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 210 - 211
  • [37] Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma
    Wahab, Ahsan
    Rafae, Abdul
    Mushtaq, Kamran
    Masood, Adeel
    Ehsan, Hamid
    Khakwani, Maria
    Khan, Aqsa
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [38] Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial
    Trudel, Suzanne
    Mccurdy, Arleigh
    Louzada, Martha L.
    Parkin, Stephen
    White, Darrell
    Chu, Michael P.
    Kotb, Rami
    Mian, Hira
    Othman, Ibraheem
    Su, Jiandong
    Khan, Aniba
    Gul, Engin
    Reece, Donna
    NATURE MEDICINE, 2024, 30 (02) : 543 - 551
  • [39] Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update
    Hultcrantz, Malin
    Kleinman, David
    Vij, Ravi
    Escalante, Fernando
    Delforge, Michel
    Kotowsky, Nirali
    Bitetti, Jacopo
    Boytsov, Natalie
    Camadoo-O'Byrne, Leena
    Happ, Lindsey Powers
    Rohman, Mujib
    Germain, Guillaume
    Duh, Mei Sheng
    Laliberte, Francois
    Mahendran, Malena
    Urosevic, Ana
    Lee, Hans
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S185 - S186
  • [40] A real-world study of belantamab mafodotin in a heavily pretreated population of multiple myeloma patients
    Bird, Sarah
    Bishop, Ellouise
    Panopoulou, Katerina
    Saso, Radovan
    Mir, Farheen
    Stern, Simon
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 60 - 61
12345